Outlook Therapeutics Inc (OTLK) Stock Price, Quote & News

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

Geek98 May. 20 at 12:38 AM

$OTLK Today is our day, wishful thinking tho

0 · Reply

FabioF91 May. 19 at 9:12 PM

$OTLK I know this guy is tormenting your nights

3 · Reply

N3xtTry May. 19 at 8:11 PM

$OTLK

1 · Reply

GenerallyGentle May. 19 at 6:05 PM

$OTLK dumps the first 30mins then sits below .225 all morning then gets bought up in the afternoon. see the pattern yet ?

0 · Reply

GooningToday May. 19 at 5:48 PM

$OTLK we are now at the part of the day where it acts like it’s going to move up but it just keeps getting stuffed and never goes anywhere

0 · Reply

farcanal May. 19 at 5:14 PM

$OTLK 😳

2 · Reply

adayxs May. 19 at 5:00 PM

$OTLK It is good to see that the market thinks Bob finally got it together. I was worried the market might still view him as a screwup.

1 · Reply

Rounderssss4 May. 19 at 4:51 PM

$OTLK I swear if this gets positive reaction from FDA I will stay away from penny stocks for a while 🤣

1 · Reply

Mychiefs1 May. 19 at 4:46 PM

$OTLK same FDA routine....wait till last second possible....getting old....hoping news lands in the middle....they will not outright reverse their decision........good luck fellow longs.....

0 · Reply

Rounderssss4 May. 19 at 4:17 PM

$OTLK ok let's get the positive PR send this sky high and then raise sounds

0 · Reply

Outlook Therapeutics downgraded to Neutral from Buy at BTIG

2026-05-15T20:18:39.000Z - 4 days ago

Outlook Therapeutics reports Q2 adjusted EPS (16c), consensus (12c)

May 15, 2026, 4:05 PM EDT - 4 days ago

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

May 15, 2026, 7:00 AM EDT - 4 days ago

Outlook Therapeutics Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 4 days ago

Outlook Therapeutics Earnings release: Q2 2026

Apr 23, 2026, 4:05 PM EDT - 26 days ago

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

2026-04-22T14:29:53.000Z - 27 days ago

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

Apr 22, 2026, 8:30 AM EDT - 27 days ago

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2026-04-21T15:24:19.000Z - 4 weeks ago

Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA

Apr 21, 2026, 9:05 AM EDT - 4 weeks ago

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

2026-04-07T13:19:03.000Z - 6 weeks ago

Outlook Therapeutics submits formal dispute resolution request to FDA

Apr 7, 2026, 8:50 AM EDT - 6 weeks ago

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

Mar 25, 2026, 4:05 PM EDT - 7 weeks ago

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Mar 24, 2026, 7:00 AM EDT - 2 months ago

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

2026-03-23T21:35:25.000Z - 2 months ago

Outlook Therapeutics announces common stock, warrant offering, no amount given

Mar 23, 2026, 5:30 PM EDT - 2 months ago

Outlook Therapeutics Announces Proposed Public Offering

2026-03-16T12:41:35.000Z - 2 months ago

Outlook Therapeutics announces $18.4M non-convertible note financing

Mar 16, 2026, 8:05 AM EDT - 2 months ago

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

2026-03-11T12:55:42.000Z - 2 months ago

Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant

2026-03-05T21:55:20.000Z - 2 months ago

Outlook Therapeutics provides update following FDA meeting on ONS-5010

Mar 5, 2026, 4:15 PM EST - 2 months ago

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

2026-02-19T14:16:05.000Z - 3 months ago

Outlook enters distribution agreement for sale of Lytenava in Switzerland

Feb 19, 2026, 9:00 AM EST - 3 months ago

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

2026-02-17T13:16:40.000Z - 3 months ago

Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)

Feb 17, 2026, 8:05 AM EST - 3 months ago

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 17, 2026, 8:00 AM EST - 3 months ago

Outlook Therapeutics Quarterly report: Q1 2026

Feb 17, 2026, 8:00 AM EST - 3 months ago

Outlook Therapeutics Earnings release: Q1 2026

2026-02-11T13:50:19.000Z - 3 months ago

Outlook Therapeutics sumbits Type A meeting request to FDA

Feb 11, 2026, 8:45 AM EST - 3 months ago

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Jan 26, 2026, 7:00 AM EST - 4 months ago

Outlook Therapeutics Proxy statement: Proxy Filing

Jan 26, 2026, 7:00 AM EST - 4 months ago

Outlook Therapeutics Proxy statement: Proxy Filing

2026-01-06T13:50:29.000Z - 4 months ago

Outlook Therapeutics appoints Laura Cantrell as VP, corporate strategy

2026-01-06T13:45:19.000Z - 4 months ago

Largest borrow rate increases among liquid names

CBRL CYPH FCEL MSTU NFE SPCE USO

Jan 6, 2026, 8:35 AM EST - 4 months ago

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

2026-01-04T13:50:18.000Z - 4 months ago

The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics

2026-01-02T23:15:07.000Z - 4 months ago

Outlook Therapeutics price target lowered to $1 from $3 at Chardan

2026-01-02T14:25:20.000Z - 4 months ago

Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright

Dec 31, 2025, 4:23 PM EST - 4 months ago

US FDA declines to approve Outlook Therapeutics' eye disease drug

Dec 31, 2025, 4:15 PM EST - 4 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Dec 26, 2025, 5:00 PM EST - 5 months ago

Outlook Therapeutics Announces New Employment Inducement Grants

Dec 19, 2025, 8:30 AM EST - 5 months ago

Outlook Therapeutics Annual report: Q4 2025

Dec 19, 2025, 8:30 AM EST - 5 months ago

Outlook Therapeutics Earnings release: Q4 2025

Dec 19, 2025, 8:05 AM EST - 5 months ago

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Dec 2, 2025, 10:00 AM EST - 6 months ago

Outlook Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 9:05 AM EST - 6 months ago

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 6 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 3, 2025, 8:35 AM EST - 7 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Sep 29, 2025, 8:45 AM EDT - 8 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 3, 2025, 8:35 AM EDT - 9 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 2, 2025, 8:35 AM EDT - 9 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Aug 28, 2025, 11:51 AM EDT - 9 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Outlook Therapeutics Transcript: Status Update

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Outlook Therapeutics Press release: Status Update

Aug 28, 2025, 6:39 AM EDT - 9 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 14, 2025, 8:05 AM EDT - 9 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Aug 14, 2025, 12:00 AM EDT - 9 months ago

Outlook Therapeutics Quarterly report: Q3 2025

Aug 14, 2025, 12:00 AM EDT - 9 months ago

Outlook Therapeutics Earnings release: Q3 2025

Jul 24, 2025, 9:00 AM EDT - 10 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 22, 2025, 8:45 AM EDT - 10 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:05 AM EDT - 11 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jul 1, 2025, 7:00 AM EDT - 11 months ago

Outlook Therapeutics Slides: Corporate Presentation

Jun 25, 2025, 12:00 PM EDT - 11 months ago

Outlook Therapeutics Transcript: Status Update

Jun 18, 2025, 9:05 AM EDT - 11 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 1 year ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 1 year ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 1 year ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

May 15, 2025, 12:30 PM EDT - 1 year ago

Outlook Therapeutics Earnings release: Q2 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

Outlook Therapeutics Quarterly report: Q2 2025

Apr 8, 2025, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Outlook Therapeutics Registration statement: Registration Filing

Feb 28, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 28, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Registration statement: Registration Filing

Feb 19, 2025, 9:00 AM EST - 1 year ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 14, 2025, 8:00 AM EST - 1 year ago

Outlook Therapeutics Quarterly report: Q1 2025

Feb 14, 2025, 8:00 AM EST - 1 year ago

Outlook Therapeutics Earnings release: Q1 2025

Feb 10, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Feb 3, 2025, 7:00 PM EST - 1 year ago

Outlook Therapeutics Transcript: Study Update

Jan 31, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 31, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Proxy statement: Proxy Filing

Jan 23, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 6:00 AM EST - 1 year ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Dec 27, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 27, 2024, 7:00 AM EST - 1 year ago

Outlook Therapeutics Annual report: Q4 2024

Dec 27, 2024, 7:00 AM EST - 1 year ago

Outlook Therapeutics Earnings release: Q4 2024

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Announces Executive Leadership Transition

Geek98 May. 20 at 12:38 AM

$OTLK Today is our day, wishful thinking tho

0 · Reply

FabioF91 May. 19 at 9:12 PM

$OTLK I know this guy is tormenting your nights

3 · Reply

N3xtTry May. 19 at 8:11 PM

$OTLK

1 · Reply

GenerallyGentle May. 19 at 6:05 PM

$OTLK dumps the first 30mins then sits below .225 all morning then gets bought up in the afternoon. see the pattern yet ?

0 · Reply

GooningToday May. 19 at 5:48 PM

$OTLK we are now at the part of the day where it acts like it’s going to move up but it just keeps getting stuffed and never goes anywhere

0 · Reply

farcanal May. 19 at 5:14 PM

$OTLK 😳

2 · Reply

adayxs May. 19 at 5:00 PM

$OTLK It is good to see that the market thinks Bob finally got it together. I was worried the market might still view him as a screwup.

1 · Reply

Rounderssss4 May. 19 at 4:51 PM

$OTLK I swear if this gets positive reaction from FDA I will stay away from penny stocks for a while 🤣

1 · Reply

Mychiefs1 May. 19 at 4:46 PM

$OTLK same FDA routine....wait till last second possible....getting old....hoping news lands in the middle....they will not outright reverse their decision........good luck fellow longs.....

0 · Reply

Rounderssss4 May. 19 at 4:17 PM

$OTLK ok let's get the positive PR send this sky high and then raise sounds

0 · Reply

Stop_PAID_PUMPERS May. 19 at 3:53 PM

$OTLK Bring it 2.33$ my purchase price.

0 · Reply

DidYouReadThis May. 19 at 3:52 PM

$OTLK Do you think Moby Dick (or his cousins) might be circling?

0 · Reply

Moneybags789 May. 19 at 3:42 PM

$OTLK NEWS PLEASE!

0 · Reply

Tonyboner May. 19 at 3:23 PM

$OTLK Will need to raise again soon. Burn is over 6 million a Q

0 · Reply

GooningToday May. 19 at 3:06 PM

$OTLK it’s hilarious that folks block people on this site when they don’t like what people say about a stock. lol…. It literally just prevents them from seeing what you say. Putting a blindfold on bc it hurts them so much to see the truth that this company has ate shit their entire history.

1 · Reply

DidYouReadThis May. 19 at 2:35 PM

$OTLK How high do you think volume will be after an announcement?

2 · Reply

DidYouReadThis May. 19 at 2:23 PM

$OTLK Can someone please try to find one example (or more) of a precedent to request a new trial after an FDDR meeting when a new trial wasn’t explicitly requested in one or more CRLS? Or an example when a request for a new trial was given in a list of choices like x months real world evidence, bridge study, 24 week trial with a 12 week primary endpoint?

2 · Reply

BADBOYROY May. 19 at 2:22 PM

$OTLK

0 · Reply

adayxs May. 19 at 2:07 PM

$OTLK I can count of this to be the only red I have. LOLOL. I said I would ride this out with the longs and that is what I will do.

2 · Reply

FabioF91 May. 19 at 2:01 PM

$OTLK another exciting day bewteen 0.21 - 0.23🥱

0 · Reply

DidYouReadThis May. 19 at 2:01 PM

$OTLK Am I misreading something, or does July 2026 only have options at 2.50, 5.00, and 7.50 strikes?

0 · Reply

GooningToday May. 19 at 1:58 PM

$OTLK dumpster fire stock, dumpster fire management

1 · Reply

Market Cap	27.57M
Revenue (ttm)	1.41M
Net Income (ttm)	-62.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,426.95%
Debt to Equity Ratio	-0.93

Volume	2,657,100
Avg Vol	4,371,472
Day's Range	N/A - N/A
Shares Out	120.86M
Stochastic %K	49%
Beta	0.32
Analysts	Sell
Price Target	$5.38